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Infection is a major source of morbidity and the leading 
cause of death in immunocompromised patients [1]. Th  e 
increased susceptibility to infection results from the 
intertwined eﬀ  ects of the immunocompromising condi-
tion, treatments, and co-morbidities [1]. Human infec-
tion with the novel H1N1 inﬂ  uenza virus was ﬁ  rst recog-
nized in early April 2009 and declared a worldwide 
pandemic by the World Health Organization in June 
2009. Recent case series provide information on the 
clinical course, risk factors, and outcome of H1N1(v) 
infection [2-4]. Both New Zealand and Canada have 
experi  enced H1N1(v) outbreaks with severe illness 
requir  ing intensive care unit (ICU) admission, ventilatory 
support, and rescue therapies. However, no case series 
have speciﬁ  cally described the features of H1NI(v) infec-
tion in immunocompromised patients. Here, we report 
the clinical and epidemiologic features in 10 critically ill 
immunocompromised patients with H1N1(v) infection.
Th  e case deﬁ   nition was ICU admission for acute 
respira  tory failure and a positive speciﬁ  c  polymerase 
chain reaction test for the pandemic inﬂ  uenza A (H1N1) 
2009 virus. All patients meeting this case deﬁ  nition were 
included.
In late 2009, 15 patients with H1N1-related acute 
respiratory failure, including 10 immunocompromised 
patients, required ICU admission. As reported in Table 1, 
median time from respiratory symptom onset to ICU 
admission was 4  days (interquartile range [IQR] 3 to 
5  days). Hypoxemia was mild at ICU admission but 
worsened over the next few days. Th   e chest radiographs 
consistently showed extensive pulmonary inﬁ  ltrates 
(median Murray score 3; IQR 2 to 4), and 80% of cases 
showed an alveolar pattern. All patients were treated 
with oseltamivir, which was prescribed 1 day (range 0 to 
6 days) after ICU admission. Superinfection (mostly 
bacterial pneumonia) occurred in all patients in keeping 
with previous data on seasonal inﬂ  uenza [5]. Th  e  clinical 
course was charac  terized by prolonged oxygen depen-
dency in the survivors (10 days; IQR 6 to 15 days). Death 
occurred in four patients and was usually secondary to 
severe hypoxemia.
H1N1(v) infection can result in a wide spectrum of 
clinical patterns, ranging from no symptoms to fulminant 
viral pneumonia. Th  is new pandemic virus is charac-
terized by a high prevalence of severe viral pneumonitis, 
which often requires mechanical ventilation [2]. 
Inﬂ  uenza viruses are known to cause severe infections in 
immunocompromised patients, of whom variable 
propor  tions were reported in epidemiologic descriptions 
[2-4]. Our case series is the ﬁ  rst to describe the course of 
H1N1(v) infection in immunocompromised hosts.
Several points deserve to be highlighted. First, the risk 
factors for H1N1(v) described in the overall population 
[2-4] were not found in our cohort. In contrast, none of 
our patients had obesity (median body mass index 26.9; 
IQR 21 to 26) or chronic lung disease [3]. Of our 
10 patients, 7 were on long-term steroid treatment, as 
described in the immunocompromised subgroup of the 
Canadian ICU patients [3]. Cellular immunodeﬁ  ciency is 
the main risk factor for lower respiratory tract infection 
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© 2010 BioMed Central Ltdwith inﬂ  uenza viruses [5] as the main defense mechanism 
is CD8 T-lymphocyte-mediated cytotoxicity. Th  e  clinical 
presentation in our patients was similar to that described 
in immunocompetent individuals, with symptom onset 4 
days before ICU admission [2,4]. Mortality was high 
(40%) compared with the overall population with H1N1 
2009 infection [2-4]. Th   e ICU stay was shorter than in the 
overall ICU population but the hospital stay was longer, 
perhaps because of prolonged viral shedding in lympho-
penic patients [5].
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Table 1. Clinical characteristics and outcomes of H1N1(v) critically ill immunocompromised patients
        Time,  in
         days,  from
         respiratory
 Type  of    Immuno-   symptoms      
 immune    suppressive  Lymphocyte  to  ICU  Ventilatory    Anti-infectious 
Patient defi  ciency  Chemotherapy  agents  count  admission   support  Superinfection  agentsa Outcome
1  Chronic myeloid   No  No  4,000  3  NIV  Clinically   C3G/macrolide  Alive
 leukemia           documented
2  Allogeneic BMT   No  Yes  800  1  MV  Clinically   Piperacillin/  Dead
  (12 months ago)     (steroid/CIs)        documented  FQ
 with  GVHD
3  Allogeneic BMT   No  Yes  600  1  NIV  Escherichia coli +  Imipeneme/  Dead
  (15 months ago)     (steroid/CIs)        Aspergillus fumigatus  FQ
 with  GVHD
4  Autologous BMT   Yes  Yes  50  5  None  Clinically   Piperacillin/  Alive
  for multiple myeloma    (steroid)        documented  macrolide
5 Renal  transplantation  Yes  Yes  1,200  5  MV Pseudomonas Piperacillin/  Dead
     (steroid/CIs/MMF)       aeruginosa macrolides
6 HIV  No  No  1,800  3  None  Streptococcus   C3G/  Alive
            pneumoniae macrolide
7  Autologous BMT   Yes  Yes  100  5  MV  Clinically   Piperacillin/  Alive
  for multiple myeloma    (steroid)        documented  macrolide
8 Myelodysplasia  Yes  Yes  2,000  3  MV E. coli Piperacillin/  Dead
    (steroid)         macrolide
9  Mantle cell lymphoma  No  No  100  2  NIV and MV  S. pneumoniae C3G/macrolide  Alive
10  Solid organ   No  Yes  2,000  2  None  S. pneumoniae C3G/macrolide  Alive
 transplantation   (steroid)
aAll patients were receiving oseltamivir. BMT, bone marrow transplantation; C3G, third-generation cephalosporin; CI, calcineurin inhibitor; FQ, fl  uoroquinolone; GVHD, 
graft-versus-host disease; ICU, intensive care unit; MMF, mycophenolate mofetil; MV, mechanical ventilation; NIV, non-invasive mechanical ventilation.
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